



**RECEIVED**  
NOV 07 2003  
**TECH CENTER 1600/2900**

Express Mail No.: EL 501 638 985 US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: Bermudes et al.

Application No.: 09/645,415

Group Art Unit: 1614

Filed: August 24, 2000

Examiner: To be assigned

For: COMPOSITIONS AND METHODS FOR TUMOR-TARGETED DELIVERY OF EFFECTOR MOLECULES Attorney Docket No.: 8002-059

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 C.F.R. §§ 1.56 AND 1.97**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. §§ 1.56 and 1.97 to inform the Patent Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby invite the Examiner's attention to the references AA-EZ listed on the attached revised form PTO 1449 entitled "List of References Cited by Applicant." Copies of references AA-EZ are submitted herewith.

Identification of the listed references is not meant to be construed as an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application. Consequently, Applicants respectfully decline to use form PTO-1449, since this form identifies all of the references cited therein as "Prior Art." As an alternative, Applicants submit herewith several pages of a "revised form PTO 1449" entitled "List of References Cited" instead of "List of Prior Art Cited".

Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(b), since it is believed that this information disclosure statement is being filed before the mailing date of a first Office Action on the merits, no fee is due in connection herewith. However, should the Patent Office determine

otherwise, please charge the required fee to Pennie & Edmonds LLP deposit account no. 16-1150. A duplicate copy is enclosed for accounting purposes.

Respectfully submitted,

Date August 24, 2001

Geraldine F. Baldwin 31,232  
Geraldine F. Baldwin (Reg. No.)

PENNIE & EDMONDS LLP  
1155 Avenue of the Americas  
New York, New York 10036-2711  
(212) 790-9090

Enclosures

By: Jennifer J. Chheda  
Reg No. 46,617



RECEIVED

NOV 07 2003

TECH CENTER 1600/2900

## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

8002-059-999

APPLICATION NO.

09/645,415

APPLICANT

Bermudes et al.

FILING DATE

August 24, 2000

GROUP

1614

## U.S. PATENT DOCUMENTS


*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	4,436,727	3/13/84	Ribi			
	AB	5,021,234	6/4/91	Ehrenfeld			
	AC	5,344,762	9/6/94	Karapetian			
	AD	5,824,538	10/20/98	Branstrom			
	AE	6,080,849	9/10/97	Bermudes et al.			
	EK	5,997,881	12/7/99	Powell et al.			
	EL	6,150,170	11/21/00	Powell et al.			
	EM	09/645,418		Bermudes et al.			8/24/00
	ES	5,877,159	3/2/99	Powell et al.			

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AF	WO 9106317	5/16/91	PCT				
	AG	WO 9211361	7/9/92	PCT				
	AH	WO 9502048	1/19/95	PCT				
	AI	WO 9611277	4/18/96	PCT				
	AJ	WO 9640238	12/19/96	PCT				
	AK	WO 9718837	5/29/97	PCT				
	AL	WO 9719688	6/5/97	PCT				
	AM	WO 9725061	7/17/97	PCT				
	AN	WO 9833923	8/16/98	PCT				
	EN	WO 9634631	11/7/96	PCT				
	EO	WO 9718225	5/22/97	PCT				
	EP	WO 9853854	12/3/98	PCT				
	EQ	WO 9913003	3/18/99	PCT				
	ER	WO 9952563	10/21/99	PCT				

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	AO	Adler, 1973, "A Method for Measuring Chemotaxis and Use of the Method to Determine Optimum Conditions for Chemotaxis by <i>Escherichia coli</i> ", J. Gen. Microbiol. 74:77-91.
	AP	Alizadeh et al., 1994, "Apoptosis as a Mechanism of Cytolysis of Tumor Cells by a Pathogenic Free-Living Amoeba", Infect. Immun. 62:1298-1303.




RECEIVED

NOV 07 2003

TECH CENTER 1600/2900

Sheet 2 of 5

	Anderson et al., 1996, "Development of attenuated <i>Salmonella</i> strains that express heterologous antigens", Methods in Molecular Medicine: Vaccine protocols, ed. Robinson A, Farrar G, Wiblin C., Humana Press New Jersey, pp.47-62
AR	Bagshawe, 1995, "Antibody-Directed Enzyme Prodrug Therapy: A Review", Drug Dev. Res. 34:220-230.
AS	Barry et al., 1995, "Protection Against Mycoplasma Infection Using Expression-Library Immunization", Nature 377:632-635.
AT	Barth and Morton, 1995, "The Role of Adjuvant Therapy in Melanoma Management", Cancer 75 (Suppl.):726-734.
AU	Berggren, 1995, "Recombinant <i>Salmonella</i> as an Oral HIV Vaccine", NIH Project Number 5 K08 AI01248-02.
AV	Bermudes et al., 2000, "Tumor targeted <i>Salmonella</i> . Strain development and expression of the HSV TK effector gene" Gene Therapy, Methods and Protocols, Vol. 35, 419-436
AW	Bermudes et al., 2000, "Tumor-targeted <i>Salmonella</i> . Highly selective delivery vectors", Advances in Exp. Med. And Bio. 465: 57-63
AX	Bone, 1993, "Gram-Negative Sepsis: A Dilemma of Modern Medicine", Clin. Microbiol. Rev. 6:57-68.
AY	Bonnekoh et al., 1995, "Inhibition of Melanoma Growth by Adenoviral-Mediated HSV Thymidine Kinase Gene Transfer <i>in vivo</i> ", J. Invest. Derm. 104:313-317.
AZ	Carey et al., "Clostridial Oncolysis in Man", Eur. J. Cancer 3:37-46
BA	Carrier et al., 1992, "Expression of Human IL-1 $\beta$ in <i>Salmonella typhimurium</i> ; a Model System for the Delivery of Recombinant Therapeutic Proteins <i>in vivo</i> ", J. Immunol. 148:1176-1181
BB	Carswell et al., 1975, "An Endotoxin-Induced Serum Factor that Causes Necrosis of Tumors", Proc. Natl. Acad. Sci. USA 72:3666-3670
BC	Chabalgoity et al., 1996, "A <i>Salmonella typhimurium htrA</i> Live Vaccine Expressing Multiple Copies of a Peptide Comprising Amino Acids 8-23 of Herpes Simplex Virus Glycoprotein D as a Genetic Fusion to Tetanus Toxin Fragment C Protects Mice from Herpes Simplex Virus Infection", Mol. Microbiol. 19:791-801
BD	Chen et al., 1999, "Liposomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice", Cancer Res. 59(14):Abstract.
BE	Christ et al., 1995, "E5531, a Pure Endotoxin Antagonist of High Potency", Science 268:80-83.
BF	Clairmont et al., 2000, "Biodistribution and genetic stability of the novel antitumor agent VNP 20009, a genetically modified strain of <i>Salmonella typhimurium</i> ", J. Infect. Diseases 181:1996-2002
BG	Clements, 1995, "Attenuated <i>Salmonella</i> as Vaccine Vectors", NIH Project Number 5 R01 AI 28835-06.
BH	Clementz et al., 1997, "Function of the <i>Escherichia coli msbB</i> Gene, a Multicopy Suppressor of <i>htrB</i> Knockouts, in the Acylation of Lipid A", J. Biol. Chem. 272(16):10353-10360.
BI	Cunningham et al., 1992, "Actin-Binding Protein Requirement for Cortical Stability and Efficient Locomotion", Science 255:325-327.
BJ	Curtiss, 1994, "Avirulent <i>Salmonella</i> Host-Vector Vaccine Systems", NIH Project Number 1 R41 AI36585-01.
BK	Curtiss, 1995, "Biological Containment of Live Bacterial Vaccines", NIH Project Number 1 R41 AI38599-01.
BL	Eisenstadt, 1987, "Analysis of Mutagenesis", from <i>Escherichia coli</i> and <i>Salmonella typhimurium</i> , Cellular and Molecular Biology, Neidhardt et al. (ed.), pp. 1016-1033.
BM	Eisenstein et al., 1995, "Immunotherapy of a Plasmacytoma with Attenuated <i>Salmonella</i> ", Med. Oncol. 12:103-108
BN	Engel et al., 1992, "Murein-metabolizing enzymes from <i>Escherichia coli</i> : existence of a second lytic transglycosylase", J. Bacteriol. 174:6394-6403
BO	Engelbart and Gericke, 1963, "Oncolysis by Clostridia. V. Transplanted Tumors of the Hamster", Cancer Res. 24:239-243
BP	Falkow, 1991, "Bacterial Entry into Eukaryotic Cells", Cell 65:1099-1102
BQ	Fields et al., 1989, "A <i>Salmonella</i> locus that controls resistance to microbiocidal proteins from phagocytic cells." Science 243:1059-1062
BR	Fields et al., 1986, "Mutants of <i>Salmonella typhimurium</i> that cannot survive within the macrophage are avirulent". Proc. Natl Acad Sci USA, 83:5189-5193
BS	Fox et al., 1996, "Anaerobic Bacteria as a Delivery System for Cancer Gene Therapy: <i>in vitro</i> Activation of 5-Fluorocytosine by Genetically Engineered Clostridia", Gene Therapy 3:173-178
BT	Friberg, 1993, "BCG in the Treatment of Superficial Cancer of the Bladder: A Review", Med. Oncol. Tumor Pharmacother. 10:31-36




RECEIVED

NOV 07 2003

TECH CENTER 1600/2900

Sheet 3 of 5

		Galan et al., 1990, "Cloning and characterization of the <i>asd</i> gene of <i>Salmonella typhimurium</i> : use in stable maintenance of recombinant plasmids in <i>Salmonella vaccine</i> strains", <i>Gene</i> 94:29-35
	BV	Galan, 1995, "Novel <i>Salmonella</i> Antigen Delivery Vectors", NIH Project Number 5 R01 AI36520-02.
	BW	Gericke and Engelbart, 1963, "Oncolysis by <i>Clostridia</i> . II. Experiments on a Tumor Spectrum with a Variety of <i>Clostridia</i> in Combination with Heavy Metal", <i>Cancer Res.</i> 24:217-221
	BX	Gulig, 1994, " <i>Salmonella typhimurium</i> Virulence Plasmid", NIH Project Number 5 R29 AI28421-05
	BY	Hall et al., 1994, "Induced Regression of Bovine Papillomas by Intralesional Immunotherapy", <i>Therapeutic Immunol.</i> 1:319-324
	BZ	Han et al., 1967, " <i>Salmonellosis</i> in Disseminated Malignant Diseases", <i>New Eng. J. Med.</i> 276:1045-1052.
	CA	Hoiseth and Stocker, 1981, "Aromatic dependent <i>Salmonella typhimurium</i> are non virulent and effective as live vaccines", <i>Nature</i> 291: 238-239
	CB	Jain, 1994, "Barriers to Drug Delivery in Solid Tumors", <i>Sci. American</i> 271:58-65.
	CC	Jones et al., 1992, "Invasion by <i>Salmonella typhimurium</i> is Affected by the Direction of Flagellar Rotation", <i>Infect. Immun.</i> 60:2475-2480.
	CD	Karow and Georgopoulos, 1992, "Isolation and Characterization of the <i>Escherichia coli mshB</i> Gene, a Multicopy Suppressor of Null Mutations in the High-Temperature Requirement Gene <i>htrB</i> ", <i>J. Bacteriol.</i> 174:702-710
	CE	Kelley et al., 1993, "The <i>firA</i> gene of <i>E. coli</i> encodes UDP-3-O-(R-3-hydroxymyristoyl)-glucosamine -acetyltransferase", <i>J. Biol. Chem.</i> 268:19866-19874
	CF	Khan et al., 1998, "A lethal role for lipid A in <i>Salmonella</i> Infections", <i>Mol. Microbiol.</i> 29(2):571-579
	CG	King et al., 1998, "Tumor targeted <i>Salmonella</i> expressing cytosine deaminase converted 5-fluorocytosine to 5-fluorouracil and inhibited tumor growth in vivo", <i>Proc. Of the Amer. Assoc. for Can. Res.</i> 39:512
	CH	King et al., 2000, "Tumor Therapy using <i>Salmonella</i> ", <i>Emerging Drugs</i> 5:211-219
	CI	Klimpel et al., 1990, "Bacteria-Infected Fibroblasts have Enhanced Susceptibility to the Cytotoxic Action of Tumor Necrosis Factor", <i>J. Immunol.</i> 145:711-717
	CJ	Lee et al., 1992, "Identification of a <i>Salmonella typhimurium</i> Invasion Locus by Selection for Hyperinvasive Mutants", <i>Proc. Natl. Acad. Sci. USA</i> 89:1847-1851
	CK	Lemmon et al., 1994, "Anaerobic Bacteria as a Gene Delivery System to Tumors", <i>Proc. Am. Assn. Cancer Res.</i> 35:374 (Abstract 2231)
	CL	Lemmon et al., 1997, "Anaerobic Bacteria as a Gene Delivery System that is Controlled by the Tumor Microenvironment", <i>Gene Therapy</i> , 4:791-796.
	CM	Levine, 1995, "Recombinant and Live Oral <i>Salmonella typhi</i> Vaccines", NIH Project Number 5 R01 AI29471-06.
	CN	Lindgren et al., 1996, "Macrophage killing is an essential virulence mechanism of <i>Salmonella typhimurium</i> ", <i>PNAS</i> , 93(9) 4197-4201
	CO	Loppnow et al., 1990, "Cytokine Induction by Lipopolysaccharide (LPS) Corresponds to Lethal Toxicity and is Inhibited by Nontoxic <i>Rhodobacter capsulatus</i> LPS", <i>Infect. Immun.</i> 58:3743-3750
	CP	Low et al., 1999, "VNP20009, a genetically modified <i>Salmonella Typhimurium</i> for treatment of solid tumors", <i>Proc. Amer. Assoc. For Can. Res.</i> 40:87
	CQ	Low et al., 1999, "Lipid A mutant <i>Salmonella</i> with suppressed virulence and TNF $\alpha$ induction retain tumor-targeting in vivo", <i>Nature Biotechnology</i> , 17:37-41.
	CR	Lytvyn et al., 1992, "Comparison of the Thymidine Kinase Genes from Three Entomopoxviruses", <i>J. Gen. Virol.</i> 73:3235-3240
	CS	Macnab, 1992, "Genetics and Biogenesis of Bacterial Flagella", <i>Ann. Rev. Genet.</i> 26:131-158.
	CT	Mahan et al., 1993, "Selection of Bacterial Virulence Genes that are Specifically Induced in Host Tissues", <i>Science</i> 259:686-688
	CU	Marr et al., 1997, "Tumor immunotherapy using an adenoviral vector expressing a membrane-bound mutant of murine TNF $\alpha$ ", <i>Gene Therapy</i> 4(11): Abstract
	CV	McLaughlin et al., 1979, "Synergistic Activity of Components of <i>Mycobacteria</i> and Mutant <i>Salmonella</i> in Causing Regression of Line-10 Tumors in Guinea Pigs", <i>Cancer Res.</i> 39:1766-1771
	CW	Michalek, 1994, "Genetically Engineered Oral Vaccines and Caries Immunity", Abstract, NIH Project Number 5 R01 DE09081-05




# RECEIVED

NOV 07 2003

Sheet 4 of 5

TECH CENTER 1600/2900

CX	Miller, 1995, "Entry into Eukaryotic Cells by Salmonella and Yersinia", NIH Project Number 5 K04 AI01230-02
CY	Miller et al., 1992, "An Unusual <i>pagC::TnpA</i> Mutation Leads to an Invasion- and Virulence-Defective Phenotype in <i>Salmonellae</i> ", <i>Infect. Immun.</i> 60:3763-3770
CZ	Miller et al., 1989, "A Two-Component Regulatory System ( <i>phoP phoQ</i> ) Controls <i>Salmonella typhimurium</i> Virulence", <i>Proc. Natl. Acad. Sci. USA</i> 86:5054-5058
DA	Minton et al., 1995, "Chemotherapeutic Tumor Targeting Using Clostridial Spores", <i>FEMS Micro. Rev.</i> 17:357-364
DB	Möse and Möse, 1963, "Oncolysis by Clostridia. I. Activity of <i>Clostridium butyricum</i> (M-55) and Other Nonpathogenic Clostridia Against the Ehrlich Carcinoma", <i>Cancer Res.</i> 24:212-216
DC	Mullen et al., 1992, "Transfer of the Bacterial Gene for Cytosine Deaminase to Mammalian Cells Confers Lethal Sensitivity to 5-Fluorocytosine: a Negative Selection System", <i>Proc. Natl. Acad. Sci. USA</i> 89:33-37
DD	Nauts et al., 1953, "A Review of the Influence of Bacterial Infection and of Bacterial Products (Coley's Toxins) on Malignant Tumors in Man", <i>Acta Medica Scandinavica</i> 145 (Suppl. 276):1-105
DE	O'Callaghan et al., 1988, "Characterization of aromatic and purine dependent <i>Salmonella typhimurium</i> : Attenuation, persistence, and ability induce protective immunity in BALB/c mice", <i>Infect. And Immun.</i> 56:419-423
DF	Pan et al., 1995, "A Recombinant <i>Listeria monocytogenes</i> Vaccine Expressing a Model Tumor Antigen Protects Mice Against Lethal Tumor Cell Challenge and Causes Regression of Established Tumors", <i>Nature Medicine</i> 1:471-477
DG	Parker et al., 1947, "Effect of Histolyticus Infection and Toxin on Transplantable Mouse Tumors", <i>Proc. Soc. Exp. Biol. Med.</i> 16124:461-467
DH	Pawelek et al., 1995, "Macrophage Characteristics of Metastatic Melanoma", <i>J. Invest. Dermatol.</i> 104:605 (Abstract 304)
DI	Pawelek et al., 1997, "Tumor-targeted <i>Salmonella</i> as a Novel Anti-cancer Vector", <i>Cancer Res.</i> 57:4537-4544.
DJ	Pidhemey et al., 1993, "In vitro and in vivo Tumoricidal Properties of a Pathogenic Free-Living Amoeba", <i>Cancer Letters</i> 72:91-98
DK	Platt et al., 2000, "Anti tumor effects of genetically engineered Salmonella in combination with radiation", <i>Eur. J. Cancer</i> , 36: 2397-2402
DL	Pugsley, 1988, "Protein Secretion Across the Outer Membrane of Gram-Negative Bacteria" In: <i>Protein Transfer and Organelle Biogenesis</i> , D and Robbins (eds.), Academic Press, Inc., Harcourt Brace Jovanovich, Publishers, San Diego, pp. 607-652
DM	Raue and Cashel, 1975, "Regulation of RNA Synthesis in <i>Escherichia coli</i> ", <i>Biochimica et Biophysica Acta</i> 383:290-304
DN	Reinhard et al., 1950, "Chemotherapy of Malignant Neoplastic Diseases", <i>JAMA</i> 142:383-390
DO	Saltzman et al., 1996, "Attenuated <i>Salmonella typhimurium</i> Containing Interleukin-2 Decreases MC-38 Hepatic Metastases: a Novel Anti-Tumor Agent", <i>Cancer Biotherapy and Radiopharmaceuticals</i> 11:145-153
DP	Schafer et al., 1992, "Induction of a Cellular Immune Response to a Foreign Antigen by a Recombinant <i>Listeria monocytogenes</i> Vaccine", <i>J. Immunol.</i> 149:53-59
DQ	Schlechte and Elbe, 1988, "Recombinant Plasmid DNA Variation of <i>Clostridium oncolyticum</i> - Model Experiments of Cancerostatic Gene Transfer", <i>Zbl. Bakt. Hyg. A</i> 268:347-356
DR	Schlechte et al., 1982, "Chemotherapy for Tumours Using Clostridial Oncolysis, Antibiotics and Cyclophosphamide: Model Trial on the UVT 15264 Tumor", <i>Arch. Geschwulstforsch.</i> 52:41-48
DS	Shaw et al., 1991, "The Human Dioxin-Inducible NAD(P)H: Quinone Oxidoreductase cDNA-Encoded Protein Expressed in COS-1 Cells is Identical to Diaphorase 4", <i>Eur. J. Biochem.</i> 195:171-176
DT	Sizemore et al., 1995, "Attenuated <i>Shigella</i> as a DNA Delivery Vehicle for DNA-Mediated Immunization", <i>Science</i> 270:299-302
DU	Sizemore et al., 1997, "Interaction- of <i>salmonella typhi</i> strains with cultured human monocyte-derived macrophages", <i>Infect. Immunity</i> 65:309-312
DV	Slauch et al., 1994, "In vivo Expression Technology for Selection of Bacterial Genes Specifically Induced in Host Tissues", <i>Meth. Enzymol.</i> 235:481-492
DW	Somerville et al., 1996, "A Novel <i>Escherichia coli</i> Lipid A Mutant that Produces an Antiinflammatory Lipopolysaccharide", <i>J. Clin. Invest.</i> 97:359-365
DX	Sosnowski et al., 1994, "Complications of Bacillus Calmette-Guerin (BCG) Immunotherapy in Superficial Bladder Cancer", <i>Comp. Ther.</i> 20:695-701
DY	Sternberg and Maurer, 1991, "Bacteriophage mediated generalized transduction in <i>Escherichia coli</i> and <i>Salmonella typhimurium</i> ", <i>Methods in Enzymology</i> , 204:18-43



DZ	Su et al., 1992, "Extracellular Export of Shiga Toxin B-Subunit/Haemolysin A (C-terminus) Fusion Protein Expressed in <i>Salmonella typhimurium</i> aroA-Mutant and Stimulation of B-Subunit Specific Antibody Responses in Mice", <i>Microbial Pathogenesis</i> 13:465-476
EA	Sunshine et al., 1997, "Mutation of the <i>htrB</i> Gene in Virulent <i>Salmonella typhimurium</i> Strain by Intergeneric Transduction: Strain Construction and Phenotypic Characterization", <i>J. Bacteriol.</i> , 179(17):5521-5533.
EB	Sznol et al., 2000, "Use of preferentially replicating bacteria for treatment of cancer", <i>J. Clinical Invest.</i> , 105:1027-1030
EC	Takayma et al., 1989, "Diphosphoryl Lipid A from <i>Rhodopseudomonas sphaeroides</i> ATCC 17023 Blocks Induction of Cachectin in Macrophages by Lipopolysaccharide", <i>Infect. Immun.</i> , 57:1336-1338
ED	Thiele et al., 1963, "Oncolysis by Clostridia. IV. Effect of Nonpathogenic Clostridial Spores in Normal and Pathological Tissues", <i>Cancer Res.</i> 24:234-238
EE	Thiele et al., 1963, "Oncolysis by Clostridia. III. Effects of Clostridia and Chemotherapeutic Agents on Rodent Tumors", <i>Cancer Res.</i> 24:222-232
EF	Tuomanen, 1993, "Subversion of Leukocyte Adhesion Systems by Respiratory Pathogens", <i>Am. Soc. Microbiol.</i> 59:292-296
EG	Vaara et al., 1999, "Outer membrane permeability barrier in <i>Escherichia coli</i> mutants that are defective in the late acyltransferases of lipid A biosynthesis", <i>J. Bacteriol.</i> 143(6):1459-1462
EH	Vinopal, 1987, "Selectable Phenotypes", from <i>Escherichia coli</i> and <i>Salmonella typhimurium</i> , <i>Cellular and Molecular Biology</i> , Neidhardt et al. (ed.), pp. 990-1015
EI	Wolfe et al., 1971, "Salmonellosis in Patients with Neoplastic Disease", <i>Arch. Intern. Med.</i> 128:547-554
EJ	Zheng et al., 1997, "Attenuated <i>Salmonella typhimurium</i> inhibited tumor metastasis in vivo" <i>Proc Amer Assoc. Can Res.</i> 38:9
ET	Somerville et al., 1999, "Escherichia coli msbB Gene as a Virulence Factor and a Therapeutic Target", <i>Infect. And Immunity</i> 67(12): 6583-6590
EU	Lee et al., 2000, "Comparative evaluation of the acute toxic effects in monkeys, pigs, and mice of a genetically engineered <i>Salmonella</i> strain (VNP20009) being developed as an anti-tumor agent", <i>Int. J. of Toxicology</i> , 19:19-25
EV	Luo et al., 1999, "Genetically modified <i>Salmonella typhimurium</i> inhibited growth of primary tumors and metastases", Abstract #3146. <i>Proc. Amer. Assoc. For Cancer Res.</i> 40:476
EW	Tacket et al., 1992, "Comparison of the safety and immunogenicity of aroC aroD and cya crp <i>Salmonella typhi</i> strains in adult volunteers", <i>Infect. Immun.</i> , 60:536-541
EX	Hohmann et al., 1996, "Evaluation of a phoP/phoQ-deleted, aroA-deleted live oral <i>Salmonella typhi</i> vaccine strain in human volunteers", <i>Vaccine</i> 14:19-24
EY	Tacket et al., 1997, "Safety of live oral <i>Salmonella typhi</i> vaccine strains with deletions in <i>htrA</i> and <i>aroC</i> and immune response in humans", <i>Infect. Immun.</i> 65(2):452-456
EZ	Tacket et al., 2000, "Phase 2 clinical trial of attenuated <i>Salmonella enterica</i> serovar typhi oral live vector vaccine CVD 908- <i>htrA</i> in US volunteers", <i>Infect. Immun.</i> 68(3):1196-1201

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


# POST OFFICE TO ADDRESSEE



EL501638985US

EL501638985US

SEE REVERSE SIDE FOR  
SERVICE GUARANTEE AND LIMITS  
ON INSURANCE COVERAGE



Customer Copy  
Label 11-F July 1997

## ORIGIN (POSTAL USE ONLY)

PO ZIP Code <b>10017</b>	Day of Delivery <input checked="" type="checkbox"/> Next <input type="checkbox"/> Second	Flat Rate Envelope <input type="checkbox"/>
Date In <b>8-24-01</b>	<input checked="" type="checkbox"/> 12 Noon <input type="checkbox"/> 3 PM	Postage <b>\$ 61.90</b>
Time In <b>19:06</b>	<input type="checkbox"/> 2nd Day <input type="checkbox"/> 3rd Day	Return Receipt Fee
Weight <b>29 lbs 9 ozs</b>	Int'l Alpha Country Code	COD Fee Insurance Fee
No Delivery <input type="checkbox"/> Weekend <input type="checkbox"/> Holiday	Acceptance Clerk Initials <b>(Signature)</b>	Total Postage & Fees <b>\$ 61.90</b>

## CUSTOMER USE ONLY

### METHOD OF PAYMENT:

Express Mail Corporate Acct. No.

Federal Agency Acct. No. or  
Postal Service Acct. No.

☐ **WAIVER OF SIGNATURE** (Domestic Only) Additional merchandise insurance is not a waiver of signature requested. Postage delivery to be made without obtaining signature of addressee or addressee's agent. If delivery is made without signature, carrier will attempt to deliver to secure location and leave with nearest authorized person. Signature required for delivery to secure location.

☐ **NO DELIVERY** ☐ Weekend ☐ Holiday

929  
EC2  
112

FROM: (PLEASE PRINT)

PHONE

**PENNIE & EDMONDS LLP  
1155 AVENUE OF THE AMERICAS  
17TH FL  
NEW YORK NY 10036-2711**

TO: (PLEASE PRINT)

PHONE

**ASSISTANT COMMISSIONER  
FOR PATENTS  
WASHINGTON DC 20231-9999**

**PRESS HARD.**

You are making 3 copies.

**FOR PICKUP OR TRACKING CALL 1-800-222-1811**

**www.usps.gov**





RECEIVED

NOV 07 2003

TECH CENTER 1600/2900

Express Mail No. EL 501 638 985 US First Class Mail ( )  
Date Mailed August 24, 2001  
Serial No. 097645, 415 Filed August 24, 2000  
Inventor Bermudes et al.  
For COMPOSITIONS AND METHODS FOR TUMOR-TARGETED  
DELIVERY OF EFFECTOR MOLECULES

- |  |  |
|--|--|
| <input type="checkbox"/> Affidavit/Declaration   | <input type="checkbox"/> Fee Address Indication Form   |
| <input type="checkbox"/> Amendment <input type="checkbox"/> Response                                       | <input type="checkbox"/> Fee Calculation   |
| <input type="checkbox"/> Application _____ pages   | <input type="checkbox"/> Issue Fee Transmittal   |
| <input type="checkbox"/> _____ claims _____ drawing sheets   | <input type="checkbox"/> Notice of Appeal  |
| <input type="checkbox"/> Assignment <input type="checkbox"/> Cover Sheet                                   | <input type="checkbox"/> Oral Hearing Request/Confirm  |
| <input type="checkbox"/> Brief (in triplicate)   | <input type="checkbox"/> Petition to Extend Time _____ month(s)  |
| <input type="checkbox"/> Declaration & Power of Attorney   | <input type="checkbox"/> Petition under 37 C.F.R. _____  |
| <input type="checkbox"/> Executed <input type="checkbox"/> Unexecuted <input type="checkbox"/> Copy        | <input type="checkbox"/> Power of Attorney   |
| <input type="checkbox"/> Declaration of Inventor(s)  | <input type="checkbox"/> by Assignee <input type="checkbox"/> Associate <input type="checkbox"/> with Revocation |
| <input type="checkbox"/> Executed <input type="checkbox"/> Unexecuted <input type="checkbox"/> Copy        | <input type="checkbox"/> Request for Correction of Filing Receipt  |
| <input type="checkbox"/> Design Application  | <input type="checkbox"/> Sequence Listing w/Computer Readable and Paper Copy                                     |
| <input type="checkbox"/> Disclaimer <input type="checkbox"/> Disclaimer Fee                                | <input type="checkbox"/> Small Entity Statement  |
| <input checked="" type="checkbox"/> Disclosure Statement <input checked="" type="checkbox"/> Form PTO-1449 | <input type="checkbox"/> Status Letter   |
| <input checked="" type="checkbox"/> w/refs. <input type="checkbox"/> w/o refs. <u>AA-EZ</u>                | <input type="checkbox"/> Transmittal Letter  |
| <input type="checkbox"/> Drawings, Formal  |  |
| _____ Sheets _____ Figures   |  |

Other: \_\_\_\_\_

File No. 8002-059 Sender: GFB/JJC

